ZNRF3 Antibody (2035A) [CoraFluor™ 1]
Novus Biologicals, part of Bio-Techne | Catalog # FAB8328CL1
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Concentration
Product Specifications
Immunogen
Lys53-Met216
Accession # Q5SSZ7
Specificity
Clonality
Host
Isotype
Description
CoraFluor(TM) 1, amine reactive
CoraFluor(TM) 1, thiol reactive
For more information, please see our CoraFluor(TM) TR-FRET technology flyer.
Scientific Data Images for ZNRF3 Antibody (2035A) [CoraFluor™ 1]
Product Feature: CoraFluor Probes for TR-FRET
CoraFluor™ 1, amine reactive (Catalog:7920) and CoraFluor™ 2, amine reactive (Catalog # 7950) are terbium-based probes that have been developed for use as TR-FRET donors. They emit wavelengths compatible with commonly used fluorescent acceptor dyes such as BODIPY® (or BDY) and Janelia Fluor® dyes, FITC (Catalog # 5440), TMR and Cyanine 5 (Catalog # 5436). CoraFluor™ fluorescence is brighter and more stable in biological media than existing TR-FRET donors, leading to enhanced sensitivity and improved data generation. CoraFluor™ 1 exhibits excitation upon exposure to a 337 nm UV laser.Applications for ZNRF3 Antibody (2035A) [CoraFluor™ 1]
Immunocytochemistry
Formulation, Preparation, and Storage
Purification
Formulation
Preservative
Concentration
Shipping
Stability & Storage
Background: ZNRF3
The cell-surface transmembrane E3 ubiquitin ligase zinc and ring finger 3 (ZNRF3) and its homologue ring finger 43 (RNF43) are negative feedback regulators of Wnt signaling. ZNRF3 is associated with the Wnt receptor complex, and inhibits Wnt signaling by promoting the turnover of frizzled and LRP6. R-spondin may enhance Wnt signaling by inhibiting ZNRF3. ZNRF3 may be a target for therapeutic exploration.
Long Name
Alternate Names
Additional ZNRF3 Products
Product Documents for ZNRF3 Antibody (2035A) [CoraFluor™ 1]
Product Specific Notices for ZNRF3 Antibody (2035A) [CoraFluor™ 1]
CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.